| Bioactivity | D5B is a potent and selective PD-L1 inhibitor. D5B has been modified by DBCO. The EC50 of D5B degrading PD-L1 in 4T1 and B16-F10 tumor cells are 5.4 μM and 6.2 μM, respectively. D5B can block PD-L1/PD-1 interaction and has anti-tumor activity[1]. |
| Target | EC50: 5.4 μM (PD-L1 in 4T1 tumor cells)EC50: 6.2 μM (PD-L1 in B16-F10 tumor cells) |
| Invitro | D5B (0-10 μM；24 小时) 在 4T1 和 B16-F10 肿瘤细胞中能够降解 PD-L1，EC50 分别为 5.4 μM 和 6.2 μM[1]。D5B (0-5 μM；48 小时) 在 IFN-γ 处理和叠氮化物标记的 4T1 和 B16-F10 肿瘤细胞中，显著降低细胞膜表面 PD-L1 丰度[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> D5B 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | D5B (5 mg/kg；静脉注射；单剂量) 在小鼠肿瘤模型中具有抗肿瘤的作用，与放疗联合效果更好。(D5B 为 PCPGd@D5B 纳米颗粒形式)[1] MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C58H66N2O12 |
| Molar Mass | 983.15 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hou B, et al. Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapy. Sci Adv. 2024 Nov 15;10(46):eadq3940. |